CCL25



CCL25

Q1QQ1G2GG2A3AA3F4FF4E5EE5D6DD6C7CC7C8CC8L9LL9G10GG10Y11YY11Q12QQ12H13HH13R14RR14I15II15K16KK16W17WW17N18NN18V19VV19L20LL20R21RR21H22HH22A23AA23R24RR24N25NN25Y26YY26H27HH27Q28QQ28Q29QQ29E30EE30V31VV31S32SS32G33GG33S34SS34C35CC35N36NN36L37LL37R38RR38A39AA39V40VV40R41RR41F42FF42Y43YY43F44FF44R45RR45Q46QQ46K47KK47... and 74 more residue(s)...... and 74 more residue(s)

SMILES None
InChIKey None
Sequence QGAFEDCCLGYQHRIKWNVLRHARNYHQQEVSGSCNLRAVRFYFRQKVVCGNPEDMNVKRAIRILTARKRLVHWKSASDSQTERKKSNHMKSKVENPNSTSVRSATLGHPRMVMMPRKTNN

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CCL25

Q1QQ1G2GG2A3AA3F4FF4E5EE5D6DD6C7CC7C8CC8L9LL9G10GG10Y11YY11Q12QQ12H13HH13R14RR14I15II15K16KK16W17WW17N18NN18V19VV19L20LL20R21RR21H22HH22A23AA23R24RR24N25NN25Y26YY26H27HH27Q28QQ28Q29QQ29E30EE30V31VV31S32SS32G33GG33S34SS34C35CC35N36NN36L37LL37R38RR38A39AA39V40VV40R41RR41F42FF42Y43YY43F44FF44R45RR45Q46QQ46K47KK47... and 74 more residue(s)...... and 74 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.